SOUTH PLAINFIELD, N.J., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Admera Health (www.admerahealth.com), an advanced molecular diagnostics company, announced today that its genetic testing services are now available as in-network benefits under CareFirst Blue Cross Blue Shield. With over 3.2 million members, CareFirst offers the widest coverage and the largest network for medical, dental and vision insurance in Maryland, Washington D.C., and Northern Virginia. Their expansive network provides members with access to more than 1 million physicians, provider facilities, hospitals, and care centers. CareFirst has been providing health insurance to the region for over 75 years and is nationally recognized for its customer service for their members.
Admera Health offers the most comprehensive pharmacogenomics testing services available, its PGxOne™ Plus test interrogates over 50 genes with coverage of over 200 genetic variants and provides recommendations on over 300 drugs and over 300 medical conditions. Beyond Pharmacogenomics, Admera Health also offers LiquidGx™ (a liquid biopsy test), OncoGxOne™, and OncoGxSelect™ for tumor profiling to guide the selection of targeted therapies, cancer supportive care, and inherited cardiovascular diseases via its partnership with Health in Code.
CareFirst beneficiaries will be able to receive genetic tests that utilize the latest genomic technologies to provide recommendations on medications based on a person’s genetic profile. “By utilizing CareFirst extensive list in-network partners, Admera Health will be able to help provide genetic tests to those patients who may not have access to them previously,” said Guanghui Hu, Ph.D., President and CEO of Admera Health. “Admera Health believes molecular diagnostic and genetic tests should be available to all patients all around the world and by expanding in-network insurance coverage, this is one positive step to making this goal a reality”.
About Admera Health
Admera Health is a CLIA-certified and CAP-accredited advanced molecular diagnostics company focused on personalized medicine, non-invasive cancer testing, digital health, and providing research use only services. Research and development efforts are dedicated to developing cutting-edge diagnostics that span the continuum of care. Utilizing next generation technology platforms and advanced bioinformatics, Admera Health seeks to redefine disease screening, diagnosis, treatment, monitoring, and management through its innovative, personalized solutions. It is our mission to deliver transformative, valuable solutions for patients, physicians, and clinical researchers. We are committed to improve the health and well-being of our global community through the direct delivery of personalized medically actionable results.
Admera Health Contact:
Brady Millican
VP Business Development
908-222-0533
brady.millican@admerahealth.com